Vascular Solutions Inc. (NASDAQ:VASC) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $44.27 and last traded at $43.77, with a volume of 48,172 shares trading hands. The stock had previously closed at $43.51.

Several brokerages recently issued reports on VASC. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $45.00 price target (up from $44.00) on shares of Vascular Solutions in a research note on Wednesday, April 27th. Zacks Investment Research upgraded Vascular Solutions from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research note on Thursday, April 28th. Finally, Sidoti cut Vascular Solutions from a “buy” rating to a “neutral” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $41.83.

The stock has a 50-day moving average of $40.03 and a 200 day moving average of $33.66. The company has a market capitalization of $760.15 million and a P/E ratio of 95.75.

Vascular Solutions (NASDAQ:VASC) last issued its quarterly earnings results on Monday, April 25th. The medical device company reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.02. During the same quarter in the previous year, the business earned $0.21 EPS. The company had revenue of $39 million for the quarter, compared to analysts’ expectations of $38.37 million. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. Analysts predict that Vascular Solutions Inc. will post $1.21 EPS for the current fiscal year.

In other news, CEO Howard Root sold 15,582 shares of the firm’s stock in a transaction that occurred on Wednesday, April 27th. The shares were sold at an average price of $36.07, for a total transaction of $562,042.74. Following the completion of the sale, the chief executive officer now owns 351,340 shares in the company, valued at approximately $12,672,833.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James Hennen sold 11,785 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $38.12, for a total transaction of $449,244.20. Following the sale, the chief financial officer now owns 45,073 shares of the company’s stock, valued at approximately $1,718,182.76. The disclosure for this sale can be found here.

Other large investors recently modified their holdings of the company. Nationwide Fund Advisors raised its stake in shares of Vascular Solutions by 0.5% in the fourth quarter. Nationwide Fund Advisors now owns 31,649 shares of the medical device company’s stock valued at $1,088,000 after buying an additional 153 shares during the last quarter. California State Teachers Retirement System raised its position in Vascular Solutions by 1.3% in the fourth quarter. California State Teachers Retirement System now owns 31,944 shares of the medical device company’s stock worth $1,099,000 after buying an additional 414 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Vascular Solutions by 10.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 108,609 shares of the medical device company’s stock worth $3,735,000 after buying an additional 9,965 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Vascular Solutions by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 614,337 shares of the medical device company’s stock worth $21,128,000 after buying an additional 23,334 shares in the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.